Evaluation in man of fenclozic acid (I.C.I. 54,450: Myalex), a new anti-inflamatory agent. II. Clinical trial in patients with rheumatoid arthritis.

T. Chalmers,J. Kellgren,D. S. Platt
DOI: https://doi.org/10.1136/ard.28.6.595
IF: 27.973
1969-11-01
Annals of the Rheumatic Diseases
Abstract:Inthepharmacological evaluation ofanewdrug muchistobegained byclose co-operation between clinical andindustrial research. Following initial pharmacological andtoxicological testing ofthe newcompound inlaboratory animals, thenextstep istoestablish thepharmacokinetic behaviour ofthe druginnormal humansubjects andinpatients with thedisease inwhichthedrugmayhavetherapeutic potential. Theresults ofsuchstudies withfenclozic acidhavebeendescribed inthefirst partofthis paper(Chalmers, Pohl, andPlatt, 1969). Thepurpose ofthesecond partistoreport the results ofaclinical trial ofthedruginthetreatment ofrheumatoid arthritis. Theobject ofthistrial wastocomparetheeffects ofaspirin 36g.daily withthose offenclozic acidindosages of200,300, or400mg.daily, wheneachtreatment wasgiven in randomsequence foraperiod of10days.Concomitant pharmacological studies ledtoanalterationintrial design whereby clinically unsuspected bias could bediminished.
What problem does this paper attempt to address?